Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 5/20 | 0.55 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.55 |
| ▸ | PAX8 | Q06710 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | NNMT | P40261 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21243173 | 0.82 | XDH (0.39) | XDHGDAPAX8SMN1; SMN2KDM4E | |
| SCHEMBL11036315 | 0.81 | XDH (0.60) | XDHGDAPAX8LMNATSHR | |
| SCHEMBL3915349 | 0.81 | SMN1; SMN2 (0.49) | XDHGDASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL12782649 | 0.81 | XDH (0.38) | XDHGDAPAX8LMNATSHR | |
| SCHEMBL4253369 | 0.77 | XDH (0.51) | XDHGDAPAX8LMNATSHR | |
| SCHEMBL21243175 | 0.77 | XDH (0.35) | XDHGDAPAX8LMNATSHR | |
| SCHEMBL17143115 | 0.74 | SMN1; SMN2 (0.54) | GDAPAX8LMNATSHRSMN1; SMN2 | |
| SCHEMBL562980 | 0.74 | XDH (0.67) | XDHGDAPAX8LMNATSHR | |
| SCHEMBL11191356 | 0.74 | — | — | |
| SCHEMBL1776355 | 0.72 | XDH (0.47) | XDHGDAPAX8LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112679500-B | Preparation method of intermediate of hypoglycemic drug linagliptin | 山东罗欣药业集团恒欣药业有限公司 | 2022-03-22 | — | — | CN | claimed |
| CN-112679500-A | Preparation method of intermediate of hypoglycemic drug linagliptin | 山东罗欣药业集团恒欣药业有限公司 | 2021-04-20 | — | — | CN | claimed |
| CN-112679500-B | Preparation method of intermediate of hypoglycemic drug linagliptin | 山东罗欣药业集团恒欣药业有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-112679500-B | Preparation method of intermediate of hypoglycemic drug linagliptin | 山东罗欣药业集团恒欣药业有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-112679500-A | Preparation method of intermediate of hypoglycemic drug linagliptin | 山东罗欣药业集团恒欣药业有限公司 | 2021-04-20 | — | — | CN | disclosed |
| CN-112679500-A | Preparation method of intermediate of hypoglycemic drug linagliptin | 山东罗欣药业集团恒欣药业有限公司 | 2021-04-20 | — | — | CN | disclosed |
| WO-2019243970-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASES AND CANCER | CELLIX BIO PRIVATE LIMITED (IN) | 2019-12-26 | — | — | WO | disclosed |
| EP-2963033-B1 | BENZIMIDAZOLE-4-CARBOXAMIDE DERIVATES, THEIR PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS AND THEIR USES | UNIV SHANGHAI JIAOTONG (CN) | 2018-08-01 | — | — | EP | disclosed |
| EP-2963033-A1 | BENZIMIDAZOLE-4-CARBOXAMIDE DERIVATES, THEIR PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS AND THEIR USES | Shanghai Jiao Tong University (CN) | 2016-01-06 | — | — | EP | disclosed |
| US-8871946-B2 | Benzimidazole-4-carboxamide derivatives, their preparation methods, pharmaceutical compositions and their uses | ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2014-10-28 | — | — | US | disclosed |
| US-8871946-B2 | Benzimidazole-4-carboxamide derivatives, their preparation methods, pharmaceutical compositions and their uses | ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2014-10-28 | — | — | US | disclosed |
| EP-1611107-B1 | 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS | MERCK PATENT GMBH (DE) | 2010-08-18 | — | — | EP | disclosed |
| US-7566709-B2 | 1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders | MERCK PATENT GMBH (DE) | 2009-07-28 | — | — | US | disclosed |
| US-7566709-B2 | 1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders | MERCK PATENT GMBH (DE) | 2009-07-28 | — | — | US | disclosed |
| EP-1611094-B1 | PYRAZOLE COMPOUNDS | MERCK PATENT GMBH (DE) | 2007-06-20 | — | — | EP | disclosed |
| EP-1611122-B1 | SUBSTITUTED PYRAZOLE COMPOUNDS | MERCK PATENT GMBH (DE) | 2007-06-13 | — | — | EP | disclosed |
| US-20070105871-A1 | 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders | MERCK PATENT GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070105871-A1 | 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders | MERCK PATENT GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070010531-A1 | Substituted pyrazole compounds | MERCK PATENT GMBH (DE) | 2007-01-11 | — | — | US | disclosed |
| US-20070010531-A1 | Substituted pyrazole compounds | MERCK PATENT GMBH (DE) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010531-A1 | Substituted pyrazole compounds | HTR3A, HTR1A, HTR1D | XDH 106/4885GDA 4604/4885PAX8 3101/4885 |
| US-20070105871-A1 | 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders | HTR1A, HTR1D, HTR5A | XDH 251/4885GDA 3974/4885PAX8 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.